

Silco Pharmaceuticals Ltd

Un-Audited Financial Statement (Half Yearly)

For the Period from 01 July, 2021 to 31 December, 2021






Silco Pharmaceuticals Limited

Statement of Financial Position

As at December 31, 2021

Particulars	Notes	Amount in Taka	
		31 Dec. 2021	30 June 2021
Assets			
Non Current Assets		1,619,905,523	1,643,359,449
Property, Plant and Equipment	3.00	1,382,772,716	1,241,146,404
Right of Use Assets	4.00	5,845,049	7,619,739
Capital Work in Progress	5.00	231,287,758	394,593,305
Current Assets		1,120,488,740	1,052,230,886
Inventories	6.00	451,889,385	449,452,463
Trade Receivables	7.00	389,522,168	390,532,203
Advance, Deposits and Prepayments	8.00	133,579,123	139,804,640
Cash and Cash Equivalents	9.00	104,889,352	53,031,144
Investment In Share	10.00	40,608,712	19,410,437
Total Assets		2,740,394,263	2,695,590,335
Shareholders Equity and Liabilities			
Shareholders Equity		2,309,111,555	2,268,018,123
Share Capital	11.00	1,038,070,000	1,038,070,000
Unrealized Gain/Loss on Marketable Securities		(7,640,616)	(369,919)
Retained Earnings	12.00	1,278,682,171	1,230,318,041
Non-Current Liabilities		145,725,066	144,611,002
Lease Liability (Non Current Portion)		3,179,586	4,112,546
Deferred Tax Liability	13.00	142,545,480	140,498,457
Current Liabilities		285,557,643	282,961,209
Trade Payable	14.00	10,900,061	16,154,859
Lease Liability (Current Portion)	15.00	2,860,213	3,773,307
Payable to IPO Applicants		185,021	185,021
Creditors & Accruals	16.00	10,661,265	10,471,189
Liability for WPPF	17.00	7,590,495	10,735,596
Dividend Payable (Unclaimed)		1,186,313	1,234,260
Current Tax Liability	18.00	252,174,276	240,406,977
Total Shareholders Equity and Liabilities		2,740,394,263	2,695,590,335
Net Asset Value (NAV) per Share	26.00	22.24	21.85

The annexed notes form an integral part of these financial statements.

				
Chairman	Managing Director	Director	Company Secretary	Chief Financial Officer

SIGNED IN TERMS OF OUR ANNEXED REPORT OF EVEN DATE

Date: Dhaka
February 15, 2022

Silco Pharmaceuticals Limited
Statement of Profit or Loss and other Comprehensive Income
For the period ended December 31, 2021

Particulars	Notes	Amount in Taka			
		July 2021 to Dec. 2021	July 2020 to Dec. 2020	01/10/2021 to 31/12/2021	01/10/2020 to 31/12/2020
Turnover	19.00	321,011,511	361,290,672	135,928,990	121,295,468
Less: Cost of Goods Sold	20.00	217,166,176	247,124,136	101,520,131	83,748,056
Gross Profit		103,845,335	114,166,536	34,408,860	37,547,412
Less: Operating Expenses	21.00	47,057,196	51,637,901	21,595,619	20,839,597
Profit from Operation		56,788,139	62,528,635	12,813,240	16,707,816
Less: Financial Expenses	22.00	153,394	270,997	63,125	125,365
Less: Financial Expenses (Lease)		307,718	-	143,926	-
Non-operation Income	23.00	8,960,347	2,446,234	4,751,780	818,686
Profit before Contribution to WPPF		65,287,374	64,703,872	17,357,969	17,401,136
Less: Workers' Profit Participation/Welfare Fund (WPPF)		3,108,923	3,081,137	826,570	828,626
Profit before Income Tax		62,178,451	61,622,735	16,531,399	16,572,511
Less: Provision for Income Tax	24.00	13,814,321	15,405,684	3,543,735	4,143,128
Current Tax		11,767,298	12,303,356	2,619,242	3,370,211
Deferred Tax		2,047,023	3,102,328	924,493	772,917
Net Profit after Tax (Transferred to CE)		48,364,130	46,217,051	12,987,664	12,429,383
Other Comprehensive Income:					
Unrealized Gain/Loss on Investment		(7,270,698)	-	(6,135,986)	-
Total Comprehensive Income		41,093,432	46,217,051	6,851,679	12,429,383
Earnings per Share (EPS)	25.00	0.47	0.45	0.13	0.12

The annexed notes form an integral part of these financial statements.

সির্জাম সির্জাম

Chairman

Managing Director

Director

Company Secretary

Chief Financial Officer

Date: Dhaka

February 15, 2022

Silco Pharmaceuticals Limited
Statement of Changes in Equity
For the period ended December 31, 2021

(Amount in Taka)

Particulars	Ordinary Share Capital	Unrealized Gain/Loss on Marketable Securities	Retained Earnings	Total
Balance as at July 01, 2021	1,038,070,000	(369,919)	1,230,318,041	2,268,018,123
Net Profit/(Loss) during the period	-	-	48,364,130	48,364,130
Unrealized Gain/Loss on Marketable Shares	-	(7,270,698)	-	(7,270,698)
Balance as on Dec. 31, 2021	1,038,070,000	(7,640,616)	1,278,682,171	2,309,111,555

Statement of Changes in Equity
For the period ended December 31, 2020

(Amount in Taka)

Particulars	Ordinary Share Capital	Unrealized Gain/Loss on Marketable Securities	Retained Earnings	Total
Balance as at July 01, 2020	1,038,070,000	-	1,208,429,254	2,246,499,254
Declared 10% Cash Dividend		-	(62,758,630)	
Net Profit/(Loss) during the period	-	-	46,217,051	46,217,051
Balance as on Dec. 31, 2020	1,038,070,000	-	1,191,887,675	2,292,716,305

নাইল হাভেল

Chairman

Managing Director

Director

Company Secretary

Chief Financial Officer

Date: Dhaka
February 15, 2022

Silco Pharmaceuticals Limited

Statement of Cash Flows

For the period ended December 31, 2021

Particulars	Notes	Amount in Taka	
		July 2021 to Dec. 2021	July 2020 to Dec. 2020
A. Cash Flows from Operating Activities			
Cash received from Customers	30.00	322,021,546	240,684,849
Cash received from Non-operating income		2,405,307	46,025
Cash Paid to Suppliers	31.00	(145,349,304)	(133,469,891)
Cash Paid to Employees	32.00	(39,548,504)	(25,193,773)
Cash Paid to Others	33.00	(41,768,739)	(27,919,869)
Financial Expenses		(153,394)	(145,632)
Income Tax Paid		(6,329,464)	(317,647)
Net cash flows from operating activities		91,277,448	53,684,062
B. Cash Flows from Investing Activities			
Acquisition of Property, Plant & Equipment		(6,537,034)	(1,141,380)
Cash Received/Payments to/from FDR		-	(44,045,205)
Cash Payments for Capital Work-in-Progress		(8,766,553)	(90,245,841)
Gain on Investment		6,555,040	-
Investment in Share		(28,468,973)	-
Net cash used in investing activities		(37,217,520)	(135,432,426)
C. Cash Flows from Financing Activities			
Financial Expenses (Lease)		(307,718)	-
Principle payment (Lease)		(1,846,054)	-
Cash dividend paid		(47,947)	(20,394)
Net Cash used for financing activities		(2,201,719)	(20,394)
D. Net Increase/(Decrease) Cash and Cash Equivalents (A+B+C)		51,858,209	(81,768,758)
E. Cash and Cash Equivalents at the beginning of the period		53,031,144	101,969,302
F. Cash and Cash Equivalents at the end of the period (D+E)		104,889,353	20,200,545
Net Operating Cash Flows Per Share (NOCFPS)	27.00	0.88	0.52

সাইলকো ফার্মাসিউটিক্যালস লিমিটেড

Chairman

Managing Director

Director

Company Secretary

Chief Financial Officer

Date: Dhaka

February 15, 2022